All
Suppliers
Products
CAD Models
Diverse Suppliers
Insights
By Category, Company or Brand
All Regions
Alabama
Alaska
Alberta
Arizona
Arkansas
British Columbia
California - Northern
California - Southern
Colorado
Connecticut
Delaware
District of Columbia
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Manitoba
Maryland
Massachusetts - Eastern
Massachusetts - Western
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Brunswick
New Hampshire
New Jersey - Northern
New Jersey - Southern
New Mexico
New York - Metro
New York - Upstate
Newfoundland & Labrador
North Carolina
North Dakota
Northwest Territories
Nova Scotia
Nunavut
Ohio - Northern
Ohio - Southern
Oklahoma
Ontario
Oregon
Pennsylvania - Eastern
Pennsylvania - Western
Prince Edward Island
Puerto Rico
Quebec
Rhode Island
Saskatchewan
South Carolina
South Dakota
Tennessee
Texas - North
Texas - South
Utah
Vermont
Virgin Islands
Virginia
Washington
West Virginia
Wisconsin
Wyoming
Yukon

Pharma Company Will Shutter Plant, Cut 875 Jobs

Anna Wells
1/27/2019 | 5 min read
Subscribe

Market Watch has reported that Endo International, a generics and specialty branded pharmaceutical company with U.S. headquarters in Malvern, PA, will close its Huntsville, AL manufacturing plant, as a result of declining volumes of commoditized products. In-Pharma Technologist.com says that the Huntsville plant produces generic products for pain relievers Oxycodone and Hydrocodone, as well as the anti-inflammatory drug Prednisone.

The closure, expected over the next 16 to 18 months, will result in 875 job losses. Endo said in a press release that it expects to realize approximately $55 million to $65 million in annual net savings from the closure.

The company says it is attempting “to better match manufacturing capacity to projected future demand,” though the announcement comes on the heels of another from Endo, in early July, where it said it would voluntarily remove one of its products from the market. The extended release Opana ER painkiller became the subject of an investigation by the FDA which ultimately resulted in the organization’s request that Endo remove the drug because of a growing opioid abuse crisis. The FDA said that the benefits of Opana ER no longer outweighed the risks, and its continued abuse had led to outbreaks in HIV and hepatitis infections.

Despite the recent issue with Opana ER, at least some of the plans relating to Huntsville seem to have been in the works for a while. The company had announced last year that it would embark on restructuring that would impact the plant, though it did not, at the time, announce its intent to close it.

Next Up in Industry Trends
Bridge Collapse Reverberates Throughout Supply Chain
Show More in Industry Trends